Indian private equity firm True North could soon hold a 2.44% minority stake in Biocon Biologics India Ltd, a subsidiary of Biocon Ltd, thanks to a $100-million investment. The influx of cash values Biocon Biologics at close to $3 billion. The investment is pending regulatory approval.
Indian private equity firm True North could soon hold a 2.44% minority stake in Biocon Biologics, after its planned merger with Biocon Research, parent company Biocon Ltd said in a statement. This is thanks to a $100-million investment approved by the Biocon Biologics Ltd board, which values Biocon Biologics at close to $3 billion. The investment is pending regulatory approval.
“This investment is an endorsement of the value that Biocon Biologics has demonstrated as a global biosimilars player, having commercialized three of its molecules in developed markets like EU, U.S., Japan and Australia,” stated Kiran Mazumdar-Shaw, MD, chairperson and managing director, Biocon.
True North has invested in Biocon twice before. In 2014, when it was known as India Value Fund Advisors, the fund acquired an almost 10% stake in Syngene, Biocon’s contract research arm, and in 2003, it invested in Biocon in a pre-IPO round (the company went public in 2004).
“Biosimilars is a fast growing industry that addresses a fundamental need of bringing affordability to specialized effective biologic products. Biocon Biologics has been one of the global leaders with their early success in developing and commercializing multiple products across geographies,” added Satish Chander, partner, True North.
The current investment also represents the initial move in a new round of fundraising in 2020 that could bring in $200 million to $300 million for Biocon Biologics. Other potential investors include Temasek Holdings, a Singapore government-owned investment firm, and CDC, the UK government’s investment arm. The Biologics arm of Biocon has seen enormous growth since it was formed in 2017, and it is on target to hit $1 billion in revenue in fiscal year 2022.
Thanks to its partnership with Mylan, Biocon received its first FDA approval in 2017 for the biosimilar trastuzumab, Ogivri, which recently became commercially available in the United States. The biosimilar pegfilgrastim, Fulphila—the first biosimilar to pegfilgrastim available in the United States—was approved in 2018, and Biocon’s manufacturing facility for it this past November. Altogether, Mylan and Biocon Biologics have produced 11 molecules.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.